Cytotoxic chemotherapies, molecularly targeted therapies, immunotherapies, radiotherapy, stem cell transplants, and endocrine therapies may lead to hair disorders, including alopecia, hirsutism, hypertrichosis, and pigmentary and textural hair changes. The mechanisms underlying these changes are varied and remain incompletely understood, hampering the development of preventive or therapeutic guidelines. The psychosocial impact of chemotherapy-induced alopecia has been well documented primarily in the oncology literature; however, the effect of other alterations, such as radiation-induced alopecia, hirsutism, and changes in hair color or texture on quality of life have not been described. This article reviews clinically significant therapy-related hair disorders in oncology patients, including the underlying pathophysiological mechanisms, severity grading scales, patient-reported quality of life questionnaires, management strategies, and future translational research opportunities.Le texte complet de cet article est disponible en PDF.
Key words : anagen effluvium, brittleness, cancer patients, catagen effluvium, chemotherapy-induced alopecia, curling, depigmentation, eyebrow alopecia, eyelash alopecia, hair repigmentation, hirsutism, hyperpigmentation, hypertrichosis, hypopigmentation, straightening, trichomegaly
Abbreviations used : AE, CIA, CTCAE v5.0, EGFR, MKI, QoL, RIA
| Supported in part by National Institutes of Health/National Cancer Institute Cancer Center support grant P30 CA008748. Dr Lacouture is supported by the RJR Oncodermatology Fund. Dr Freites-Martinez is partially supported by Beca Excelencia, Academia Española de Dermatología y Venereología–Fundación Piel Sana. Dr Paus is supported by the National Institute of Health Research Manchester Biomedical Research Centre.
| Dr Shapiro has been a consultant for Aclaris, Samumed, Incyte, Replicel Life Sciences, and Shook, Hardy, and Bacon LLP, who represent Sanofi Aventis US LLC. Dr Goldfarb has a speaking, consultant, or advisory role with Adgero Biopharmaceuticals, AMAG Pharmaceuticals, Procter and Gamble, and Valeant women's health pharmaceuticals. Dr Nangia received clinical trial funding from Paxman to the Baylor College of Medicine for conduct of the SCALP trial. Dr Paus has a consultant role with or receives research funding from Giuliani/Italy and Unilever/UK, and is founder/owner of Monasterium Laboratory/Germany. Dr Lacouture has a speaking, consultant, or advisory role with Abbvie, Quintiles, Boehringer Ingelheim, AstraZeneca Pharmaceuticals, Legacy Healthcare, Foamix, Adgero Bio Pharmaceuticals, Janssen R&D, Novartis, Paxman, and Novocure, and also receives research grants from Berg and Bristol-Myers Squibb. Drs Freites-Martinez and Jimenez have no conflicts of interest to disclose.
| Date of release: May 2019
| Expiration date: May 2022